Samuel Mehr
Medical Journal Articles
| Abstract C095: [212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs) |
Read Article |
| 1033MO [212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2-positive (SSTR2+) neuroendocrine tumours (NETs): Mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44) |
Read Article |
| Interim safety and efficacy data of [ 212 Pb]VMT01 in MC1R expressing melanoma. |
Read Article |
| ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: phase 1b safety/efficacy |
Read Article |
| Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings. |
Read Article |
| Interim safety and efficacy data of [ 212 Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs). |
Read Article |
| Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings |
Read Article |
| 1198P Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings |
Read Article |
| ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Initial safety analysis. |
Read Article |
| ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA |
Read Article |
